On January 6, 2023, the Food and Drug Administration approved lecanemab as the newest treatment for Alzheimer's disease. Alzheimer's Tennessee's President and CEO, Janice Wade-Whitehead shares information behind the exciting announcement.
Lecanemab, the second in a new category of AD drugs, was accepted through the Accelerated Approval pathway for the treatment of Alzheimer’s disease under which the FDA may approve drugs for serious conditions where there is an unmet medical need and a drug is shown likely to provide a clinical benefit to patients.
The FDA says these new medications represent important advancements in the ongoing fight against Alzheimer's.
The last drug to approved to treat Alzheimer’s disease gained approval in June of 2021. It was the first in 18 years! Aducanumab works by reducing the Alzheimer’s marker amyloid in the brain, a therapy expected to slow cognitive decline in those living with early Alzheimer’s.
2021 also saw human trials begin for a vaccine designed to slow the progression of Alzheimer's!
There are currently more than 140 Alzheimer's drugs in the pipeline.
Alzheimer’s Tennessee continues to support research to improve quality of life for those living with Alzheimer’s disease.
A team of engineers at the University of Tennessee is working on computer and robotic systems to help with activities of daily life and foster independence for seniors experiencing cognitive decline.
Four out of five of the drugs in the pipeline are hopeful disease-modifying therapies. Researchers need more than 50,000 participants to complete current Clinical trials in the search for Alzheimer's treatments. To learn more about participating check out Alzheimer's Tennessee's Research Connection.
Connecting Tennesseans with research advances, advocacy opportunities and clinical trials.
Alliance for Multispecialty Research: Knoxville
AMR conducts inpatient and outpatient clinical trials at its Knoxville, Tennessee location. performs phase I, II, III, and IV clinical research trials to support the development of new drugs, devices, and vaccines. AMR includes 15 locations and 2 affiliated member centers across the continental United States. Click here to learn more about the trials underway in East Tennessee right now.
The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research. Click here to learn more about the ADNI3 Trial.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.
Explore nearly 400,000 research studies in all 50 states and in 220 countries. Click here to learn more about ClinicalTrials.gov, a resorce provided by the National Institutes of Health National Libraries of Medicine.